Compare COLD & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COLD | RCUS |
|---|---|---|
| Founded | 1903 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.1B |
| IPO Year | 2018 | 2018 |
| Metric | COLD | RCUS |
|---|---|---|
| Price | $12.84 | $21.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 8 |
| Target Price | $15.93 | ★ $29.38 |
| AVG Volume (30 Days) | ★ 7.6M | 2.1M |
| Earning Date | 11-06-2025 | 10-28-2025 |
| Dividend Yield | ★ 7.23% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,607,407,000.00 | $240,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.10 | $6.50 |
| 52 Week High | $23.52 | $26.40 |
| Indicator | COLD | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 67.28 | 42.60 |
| Support Level | $10.51 | $20.35 |
| Resistance Level | $11.33 | $26.10 |
| Average True Range (ATR) | 0.45 | 1.48 |
| MACD | 0.32 | -0.59 |
| Stochastic Oscillator | 96.90 | 18.43 |
Americold Realty Trust Inc is the world's second-largest owner and operator of temperature-controlled warehouses behind privately held Lineage Logistics. The Atlanta, Georgia-based firm owns and operates approximately 239 temperature-controlled warehouses, spanning 1.4 billion cubic feet. In 2022, the firm derived more than 80% of its revenue from the United States but also has sizable operations in Europe, Canada, Australia, and New Zealand. Americold supplements its core business by providing supply management and transportation services to its various customers. It operates as a real estate investment trust.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.